Variability in measures of mineral metabolism in children on hemodialysis: impact on clinical decision-making
- 30 June 2017
- journal article
- research article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 32 (12) , 2311-2318
Abstract
Background Variability in measures of mineral metabolism has not been studied in pediatric end stage kidney disease. We sought to determine the intra-individual variability in measures of mineral metabolism in children on hemodialysis (HD) and its impact on clinical decision-making. Methods We conducted a prospective single-center study of children (3.6–17.3 years old) on chronic HD. Serial twice weekly measures of serum calcium, phosphate and intact parathyroid hormone (PTH), as well as weekly measures of fibroblast growth factor 23 (FGF23) and vitamin D metabolites, were obtained over a 12-week period in 10 children. Samples (n = 226) were assayed in a single batch at the end of the study. Results The median intra-individual coefficient of variation (CV) calculated by 4-week blocks was 5.1–6.5% for calcium, 9.5–14.9% for phosphate and 32.7–33.4% for PTH. The median overall CV for FGF23 was 44.4%. Using the first value of each block as a reference, subsequent values would dictate a discrepant management decision 33–56%, 19–28%, and 30–33% of the time for calcium, phosphate, and PTH, respectively. Adjusting for sex and age, most of the variability in phosphate and PTH was attributable to within-participant variability. For calcium, 49% of the variability was attributable to day of blood collection (Monday vs. Friday). The median (range) of an individual participant’s values within clinical target ranges was 55% (26–86%) for calcium, 58% (0–96%) for phosphate, and 21% (0–64%) for PTH. Conclusions There is considerable intra-individual variability in measures of mineral metabolism that serve as surrogate markers for bone health in children on HD. Within a 4-week period, at least 20–30% of measures would dictate a discrepant decision from the referent measure of that month. These findings have important implications for clinical decision-making and underscore the need to base therapeutic decisions on trends rather than single measurements.Keywords
Funding Information
- National Institutes of Health (K24 DK076808, K23 DK093556, K24 DK078737)
- The Children’s Hospital of Philadelphia Center for Pediatric Clinical Effectiveness (November 2014)
This publication has 24 references indexed in Scilit:
- FGF23 induces left ventricular hypertrophyJournal of Clinical Investigation, 2011
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney DiseaseJAMA, 2011
- Elevated Fibroblast Growth Factor 23 is a Risk Factor for Kidney Transplant Loss and MortalityJournal of the American Society of Nephrology, 2011
- Renal osteodystrophy in the first decade of the new millennium: Analysis of 630 bone biopsies in black and white patientsJournal of Bone and Mineral Research, 2010
- Variability of Parathyroid Hormone and Other Markers of Bone Mineral Metabolism in Patients Receiving HemodialysisClinical Journal of the American Society of Nephrology, 2010
- Phosphorus Binders and Survival on HemodialysisJournal of the American Society of Nephrology, 2009
- Association of Hemoglobin Variability and Mortality among Contemporary Incident Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2008
- Disordered Mineral Metabolism in Hemodialysis Patients: An Analysis of Cumulative Effects in the Hemodialysis (HEMO) StudyAmerican Journal of Kidney Diseases, 2008
- Mortality Risk for Dialysis Patients With Different Levels of Serum Calcium, Phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS)American Journal of Kidney Diseases, 2008
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisNew England Journal of Medicine, 2008